KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Non-Current Liabilities (2016 - 2025)

Rigel Pharmaceuticals has reported Other Non-Current Liabilities over the past 16 years, most recently at $5.0 million for Q1 2025.

  • Quarterly results put Other Non-Current Liabilities at $5.0 million for Q1 2025, down 87.49% from a year ago — trailing twelve months through Mar 2025 was $5.0 million (down 87.49% YoY), and the annual figure for FY2024 was $5.0 million, down 87.48%.
  • Other Non-Current Liabilities for Q1 2025 was $5.0 million at Rigel Pharmaceuticals, roughly flat from $5.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for RIGL hit a ceiling of $57.5 million in Q1 2021 and a floor of $5.0 million in Q4 2024.
  • Median Other Non-Current Liabilities over the past 5 years was $42.1 million (2023), compared with a mean of $40.9 million.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 1050.66% in 2021 and later crashed 87.49% in 2025.
  • Rigel Pharmaceuticals' Other Non-Current Liabilities stood at $52.7 million in 2021, then fell by 19.84% to $42.3 million in 2022, then fell by 5.49% to $39.9 million in 2023, then tumbled by 87.48% to $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $5.0 million (Q1 2025), $5.0 million (Q4 2024), and $40.0 million (Q3 2024) per Business Quant data.